Greed is good. In my opinion we are dealing with a pretty binary outcome here. If MSB is able to replicate its previous Phase 2 results (reinforced by similar findings for the ischemic sub group data in the LVAD trial) for the 85% of ischemic patients enrolled in the phase 3 current trials, we should hope for a successful outcome. In my humble opinion, based on the bio markers of the enrolled patients group , this trial is likely to succeed because the number of MACE would have already reached its target of 540, IF, one of the cohort groups HAD NOT achieved a major reduction in hospitalisations and Terminal Cardiac Events. I explained this in greater detail on the 17th May, in my post 38618502. You have been warned that when the 540 MACE have been reached , Mesoblast will have definitive proof, (one way or another) that Revascor could be a blockbuster !
MSB Price at posting:
$1.38 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)